M. Rabaglio

LBA40 Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma

E. Piovano, M. Barretina Ginesta, F. Marme, 2023, Annals of Oncology.

Exceptional Response to Pembrolizumab in a Mismatch Repair-Deficient Aggressive Prostate Cancer with Somatic EPCAM, MSH2, and MSH6 Co-Deletion: A Case Report

Dennis Hoch, Tobias Grob, Dilara Akhoundova, 2023, Case Reports in Oncology.

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.

A. Gadducci, A. Lissoni, S. Cosio, 2024, The Lancet. Oncology.